 Connection
Everett Meyer to Hematopoietic Stem Cell Transplantation
This is a "connection" page, showing publications Everett Meyer has written about Hematopoietic Stem Cell Transplantation.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
6.481 |
|
|
|
-
Negrin RS, Meyer EH. CD4+CD25+FOXP3+ regulatory T cells to protect against graft-versus-host disease. Blood. 2026 09 10; 148(11):1381-1387.
Score: 0.629
-
Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026 Mar 12; 147(11):1168-1177.
Score: 0.608
-
Iliopoulou BP, Pathak S, Mosher B, Witherspoon L, Wells A, Bader CS, Chen PI, Nagy N, Villar-Prados A, Jensen K, Meyer EH. Synergistic venetoclax and anti-CD3 therapy for control of alloreactive response in hematopoietic stem cell transplantation. Am J Transplant. 2026 Apr; 26(4):729-743.
Score: 0.598
-
Meyer EH, Pavlova A, Villar-Prados A, Bader C, Xie B, Muffly L, Kim P, Sutherland K, Bharadwaj S, Dahiya S, Frank M, Arai S, Johnston L, Miklos D, Rezvani A, Shiraz P, Sidana S, Shizuru J, Weng WK, Agrawal V, Putnam A, Fernhoff N, Tamarisis J, Lu Y, Pawar RD, McClellan JS, Lowsky R, Negrin RS. Donor regulatory T-cell therapy to prevent graft-versus-host disease. Blood. 2025 May 01; 145(18):2012-2024.
Score: 0.573
-
Bader CS, Pavlova A, Lowsky R, Muffly LS, Shiraz P, Arai S, Johnston LJ, Rezvani AR, Weng WK, Miklos DB, Frank MJ, Tamaresis JS, Agrawal V, Bharadwaj S, Sidana S, Shizuru JA, Fernhoff NB, Putnam A, Killian S, Xie BJ, Negrin RS, Meyer EH. Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD. Blood Adv. 2024 03 12; 8(5):1105-1115.
Score: 0.529
-
Zheng P, Tamaresis J, Thangavelu G, Xu L, You X, Blazar BR, Negrin RS, Zehnder JL, Iliopoulou BP, Meyer EH. Recipient-specific T-cell repertoire reconstitution in the gut following murine hematopoietic cell transplant. Blood Adv. 2020 09 08; 4(17):4232-4243.
Score: 0.415
-
Shah O, Tamaresis JS, Kenyon LJ, Xu L, Zheng P, Gupta P, Rangarajan K, Lee S, Spellman S, Nikiforow S, Zehnder J, Meyer EH. Analysis of the Whole CDR3 T Cell Receptor Repertoire after Hematopoietic Stem Cell Transplantation in 2 Clinical Cohorts. Biol Blood Marrow Transplant. 2020 06; 26(6):1050-1070.
Score: 0.399
-
Iliopoulou BP, Hsu K, Pérez-Cruz M, Tang SW, Pang WW, Erkers T, Kambham N, Freeman GJ, Dekruyff RH, Meyer EH. Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation. Blood Adv. 2019 11 12; 3(21):3419-3431.
Score: 0.392
-
Meyer EH, Laport G, Xie BJ, MacDonald K, Heydari K, Sahaf B, Tang SW, Baker J, Armstrong R, Tate K, Tadisco C, Arai S, Johnston L, Lowsky R, Muffly L, Rezvani AR, Shizuru J, Weng WK, Sheehan K, Miklos D, Negrin RS. Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI Insight. 2019 05 16; 4(10).
Score: 0.379
-
Narayan R, Benjamin JE, Shah O, Tian L, Tate K, Armstrong R, Xie BJ, Lowsky R, Laport G, Negrin RS, Meyer EH. Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms. Biol Blood Marrow Transplant. 2019 07; 25(7):1293-1303.
Score: 0.376
-
Meyer EH, Hsu AR, Liliental J, Löhr A, Florek M, Zehnder JL, Strober S, Lavori P, Miklos DB, Johnson DS, Negrin RS. A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. Blood. 2013 Jun 13; 121(24):4955-62.
Score: 0.250
-
Bader CS, Killian S, Iliopoulou BP, Chen PI, Pathak S, Le CT, Villar-Prados A, Ji X, Jensen KP, Negrin RS, Meyer EH. Regulatory-like FOXP3+Helios+CD4+ T conventional cells correlate with T-cell activation after Orca-T immunotherapy. Blood. 2026 05 21; 147(21):2489-2502.
Score: 0.154
-
Wang L, Pulgrossi RC, Anderson J, Garcia A, Meyer EH, Zehnder JL, Pinsky BA. Assessing the Clinical Performance of a Presymptomatic Acute Graft-Versus-Host Disease Biomarker Test in Hematopoietic Stem Cell Transplant Recipients. J Appl Lab Med. 2026 Mar 05; 11(2):257-268.
Score: 0.152
-
Bader CS, Meyer EH, Negrin RS. Regulatory T cell approaches for graft-versus-host disease prevention. Curr Opin Immunol. 2026 Feb; 98:102685.
Score: 0.148
-
Liang EC, Craig J, Torelli S, Cunanan K, Iglesias M, Arai S, Frank MJ, Johnston L, Lowsky R, Meyer EH, Miklos DB, Negrin R, Rezvani A, Shiraz P, Shizuru J, Sidana S, Weng WK, Bharadwaj S, Muffly L. Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplant Cell Ther. 2022 08; 28(8):490-495.
Score: 0.117
-
Bankova AK, Caveney J, Yao B, Ramos TL, Bögeholz J, Heydari K, Diaz N, Jackson ML, Lowsky R, Brown JW, Johnston L, Rezvani AR, Frank MJ, Muffly L, Weng WK, Sidana S, Negrin RS, Miklos DB, Shiraz P, Meyer EH, Shizuru JA, Arai S. Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report. Transplant Cell Ther. 2022 04; 28(4):215.e1-215.e10.
Score: 0.114
-
Muffly L, Sundaram V, Chen C, Yurkiewicz I, Kuo E, Burnash S, Spiegel JY, Arai S, Frank MJ, Johnston LJ, Lowsky R, Meyer EH, Negrin RS, Rezvani AR, Sidana S, Shiraz P, Shizuru JA, Weng WK, Liedtke M, Vempaty HT, Miklos DB. Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Adv. 2021 08 24; 5(16):3147-3151.
Score: 0.111
-
Johnsrud A, Ladha A, Muffly L, Shiraz P, Goldstein G, Osgood V, Shizuru JA, Johnston L, Arai S, Weng WK, Lowsky R, Rezvani AR, Meyer EH, Frank MJ, Negrin RS, Miklos DB, Sidana S. Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era. Transplant Cell Ther. 2021 07; 27(7):590.e1-590.e8.
Score: 0.108
-
Liang EC, Muffly LS, Shiraz P, Shizuru JA, Johnston L, Arai S, Frank MJ, Weng WK, Lowsky R, Rezvani A, Meyer EH, Negrin R, Miklos DB, Sidana S. Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Transplant Cell Ther. 2021 05; 27(5):405.e1-405.e6.
Score: 0.107
-
Pathak S, Meyer EH. Tregs and Mixed Chimerism as Approaches for Tolerance Induction in Islet Transplantation. Front Immunol. 2020; 11:612737.
Score: 0.107
-
Erkers T, Xie BJ, Kenyon LJ, Smith B, Rieck M, Jensen KP, Ji X, Basina M, Strober S, Negrin RS, Maecker HT, Meyer EH. High-parametric evaluation of human invariant natural killer T cells to delineate heterogeneity in allo- and autoimmunity. Blood. 2020 03 12; 135(11):814-825.
Score: 0.100
-
Spinner MA, Kennedy VE, Tamaresis JS, Lavori PW, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Rezvani AR, Shizuru JA, Weng WK, Hoppe RT, Strober S, Lowsky R. Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Adv. 2019 08 27; 3(16):2454-2464.
Score: 0.097
-
Schneidawind D, Pierini A, Alvarez M, Pan Y, Baker J, Buechele C, Luong RH, Meyer EH, Negrin RS. CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells. Blood. 2014 Nov 20; 124(22):3320-8.
Score: 0.017
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|